Clinical Report: Is Cell and Gene Therapy Entering a More Mature Phase?
Overview
The discussion at ASGCT 2026 highlights key insights from industry leaders regarding cell and gene therapy (CGT).
Background
Cell and gene therapy is a developing field in treating various diseases, with ongoing advancements in regulatory guidelines and clinical trial outcomes.
Data Highlights
No numerical data provided in the source material.
Key Findings
- Companies are focusing on regulatory expectations and manufacturing scalability.
- Investment decisions and collaboration are important for CGT advancement.
- Recent guidelines have begun to codify CGT use across several diseases.
- Major trial data, such as the CARTITUDE-4 trial, indicate overall survival benefits for CGT in multiple myeloma.
- Reports indicate elimination of vaso-occlusive crises in sickle cell disease in children treated with exagamglogene autotemcel.
Clinical Implications
Healthcare professionals should stay informed about recent clinical trial outcomes.
Conclusion
Insights shared at ASGCT 2026 reflect the current state of cell and gene therapy.
Related Resources & Content
- the medicine maker, Roving Reporter Asks: What Are Recent Breakthroughs Telling Us About the CGT Field’s Maturity?, 2026 -- Recent breakthroughs in CGT
- the medicine maker, Roving Reporter Asks: What Emerging Approaches Could Define the Next Wave of Advanced Therapies?, 2026 -- Emerging approaches in advanced therapies
- the medicine maker, Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?, 2026 -- Redefining value and access in CGT
- B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology, 2026 -- NCCN guidelines on B-cell lymphomas
- Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis, 2026 -- CARTITUDE-4 trial results
- the medicine maker — We Need To Talk About Cell and Gene Therapy
- FDA Eliminates Risk Evaluation and Mitigation Strategies for CAR T cell Immunotherapies
- B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
- Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
